ELCC 2017: Clinical Progress in Immunotherapy Research in Advanced NSCLC

Speaker: Silvia Novello

Silvia Novello explains how PD-1 and PDL-1 inhibitors revolutionise the treatment of squamous tumours, particularly in smokers. 

Ongoing evaluation in the 1st-line setting could help to answer open questions and also address the needs of patients with brain metastases and oncogene-addicted NSCLC
As monotherapy or in combination with other drugs, PD-1 and PDL-1 inhibitors will certainly be part of the future treatment of lung cancer. With more and more interesting data in several settings with both 1st and 2nd line treatments, we understand more about the type of patients who could benefit from these treatments. 
However, further efficacy data on 1st line immunotherapy is still needed. Having an alternative to chemotherapy will make a big difference to patients.
In thoracic oncology, brain metastasis is a frequent issue and the new treatment algorithms may make a significant impact in that setting.

Discussion Points

  1. What does immunotherapy research brings to advanced NSCLC treatment?
  2. Which patients can benefit from immunotherapy?
  3. What are the current challenges in this field?